Holen Sie sich die Stockscreener-App
18.23
1.50%
0.27
Handel nachbörslich:
18.24
0.010
+0.05%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$17.96
Offen:
$18.14
24-Stunden-Volumen:
10.33M
Relative Volume:
0.93
Marktkapitalisierung:
$1.79B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-248.39M
KGV:
-6.777
EPS:
-2.69
Netto-Cashflow:
$-697.55M
1W Leistung:
+14.58%
1M Leistung:
-4.20%
6M Leistung:
-83.70%
1J Leistung:
-86.63%
1-Tages-Spanne:
$17.62
$19.05
1-Wochen-Bereich:
$15.34
$19.26
52-Wochen-Spanne:
$10.41
$144.22
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie SRPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
18.23 | 1.60B | 2.23B | -248.39M | -697.55M | -2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-29 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-07-29 | Bestätigt | H.C. Wainwright | Sell |
| 2025-07-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Eingeleitet | Citigroup | Sell |
| 2025-07-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-07-21 | Herabstufung | Needham | Hold → Underperform |
| 2025-07-21 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-18 | Herabstufung | Needham | Buy → Hold |
| 2025-06-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-06-17 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-06-16 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Herabstufung | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-02 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
2025-08-09 | Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline | NDAQ:SRPT | Press Release - Stockhouse
Vinay Prasad returns to role as top vaccine regulator at FDA days after leaving US agency - Reuters
SRPT INVESTOR NOTICE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - PR Newswire
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Morningstar
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - Morningstar
Securities Lawsuit Alert: Sarepta Therapeutics, Inc. (SRPT) InvestorsContact Levi & Korsinsky Before August 25, 2025 - Barchart.com
Duchenne Muscular Dystrophy Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics - Barchart.com
Elevidys sales weaken; Neumora gets into obesity - BioPharma Dive
Sarepta Therapeutics (SRPT) Declines Again On EMA - GlobeNewswire
As gene therapies falter on the market, this biopharma is aiming to defy the odds - PharmaVoice
Vor Bio hires former Sarepta exec to lead commercial strategy; Mallinckrodt poaches CFO from Incyte - Endpoints News
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Sarepta soars as revenue beats estimates on Elevidys milestone - The Boston Globe
Sarepta Shares Surge 10.46% on Record Q2 Revenue Despite Safety Scrutiny Trading Volume Ranks 407th - AInvest
SRPT DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SRPT - GlobeNewswire Inc.
Sarepta Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Class Action Filed Against Sarepta Therapeutics, Inc. - GlobeNewswire
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT)August 25, 2025 Deadline to Join – Contact The Gross Law Firm - Morningstar
Sarepta’s Stock Surges as FDA Lifts Elevidys Hold - StocksToTrade
Sarepta Gets A Price Target Hike From Wells Fargo: Retail Highlights Consistent Demand For Elevidys - Stocktwits
Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Contact Levi & Korsinsky to Join Class Action Before August 25, 2025 - ACCESS Newswire
Eli Lilly’s key obesity pill falls short of rivals, but the company still beat on earnings - statnews.com
Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries - Yahoo Finance
Cautious Outlook on Sarepta Therapeutics Amid Financial Strain and ELEVIDYS Challenges - TipRanks
Despite Safety Drama, Sarepta Beats Q2 Estimates—But No Thanks to Elevidys Sales - BioSpace
Sarepta Therapeutics stock price target raised to $50 by Wells Fargo - Investing.com
Sarepta Soars as Revenue Beats Estimates on Elevidys Milestone - Bloomberg.com
Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insig - GuruFocus
Sarepta Therapeutics Reports Strong Revenue Growth Amid Strategic Investments - TipRanks
SRPT SHAREHOLDER NEWS: The Sarepta Therapeutics, Inc. Securities Fraud Class Action is Pending -- Investors with Losses are Urged to Contact BFA Law before August 25 - ACCESS Newswire
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) InvestorsLead Plaintiff Deadline on August 25, 2025 - ACCESS Newswire
Sarepta Therapeutics (SRPT) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Sarepta Therapeutics (SRPT) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
Sarepta, with $1B in debts due in 2027, weighs efficiency measures - Fierce Pharma
Sarepta rises on strong quarterly earnings and revenue (SRPT) - Seeking Alpha
Sarepta Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sarepta Therapeutics stock up 3% on strong second quarter results, ELEVIDYS shipments resume - Investing.com Australia
Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments - Sarepta Therapeutics
Sarepta Therapeutics, Inc. SEC 10-Q Report - TradingView
Sarepta reportedly hired Trump-linked lobbying firm after gene therapy deaths - Seeking Alpha
Sarepta hired a Trump-connected firm to lobby on Duchenne treatment - statnews.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSRPT - PR Newswire
SRPT CLASS ACTION ALERT: BFA Law Reminds Sarepta Therapeutics Investors to Contact the Firm by August 25 Court Deadline to Potentially Recover Losses - Newsfile
SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Join Class Action Before August 25, 2025Contact Levi & Korsinsky - TradingView
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
Sarepta’s Future in Gene Therapy Remains Clouded, But Data From Partner Hansa Is a Bright Spot - MedCity News
SRPT LEGAL REMINDER: Why is Sarepta Therapeutics, Inc. Being Sued For Fraud? Investors With Losses are Reminded to Contact BFA Law by August 25 - ACCESS Newswire
Sarepta Therapeutics (SRPT) Announces Restructuring and ELEVIDYS Black Box Warning, EMA Recommends Refusal of Marketing Authorization, Securities Class Action Pending – Hagens Berman - GlobeNewswire
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
3.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):